Colds and flu

26 August 2014

Japan ready to offer flu drug for Ebola treatment

Japan offers to provide anti-influenza drug for possible Ebola treatment


Japan said Monday it is ready to provide a Japanese-developed anti-influenza drug as a possible treatment for the rapidly expanding Ebola outbreak.

Chief Cabinet Secretary Yoshihide Suga told reporters that Japan can offer favipiravir, developed by a subsidiary of Fujifilm Holdings Corp., at any time at the request of the World Health Organization.

The drug, with the brand name Avigan, was developed by Fujifilm subsidiary Toyama Chemical Co. to treat new and re-emerging influenza viruses, and has not been proven to be effective against Ebola.

Favipiravir was approved by Japan's health ministry in March for use against influenza. Fujifilm is in talks with the U.S. Food and Drug Administration on clinical testing of the drug in treating Ebola, company spokesman Takao Aoki said.

He said Ebola and influenza viruses are the same general type, and a similar response can theoretically be expected from Ebola.

Favipiravir inhibits viral gene replication within infected cells to prevent propagation, while other anti-viral drugs often are designed to inhibit the release of new viral particles to prevent the spread of infection, the company said.

The company has enough stock of favipiravir for more than 20,000 patients, Aoki said.

Read: Is it Ebola or is it flu?

Suga, the Cabinet spokesman, said Japan is watching for a decision by WHO that would provide more details on the use of untested drugs against Ebola. In case of an emergency, Japan may respond to individual requests before any further decision by WHO, he said.

WHO said earlier this month that it is ethical to use untested drugs on Ebola patients given the magnitude of the outbreak.

Several drugs are being developed for the treatment of Ebola. They are still in the early stages and there is no proven treatment or vaccine for the often fatal disease.

Recently, two American doctors recovered from Ebola after being treated with the experimental drug ZMapp, though it was unclear whether they were cured by the drug.

ZMapp, developed by Mapp Biopharmaceutical Inc., had never been tested on humans, although an early version worked in some Ebola-infected monkeys. It is aimed at boosting the immune system's efforts to fight off Ebola.

Ebola has killed more than 1,400 people in West Africa in the latest outbreak.

Read more:
Most South Africans go to work when they have the flu
Colds and flu can cause stroke in kids
Pregnant women should get influenza vaccine

Image: Injection from Shutterstock

See breaking news and the hottest health tips before anybody else by joining South Africa’s biggest and best health community, like health24 on Facebook now!



Read Health24’s Comments Policy

Comment on this story
Comments have been closed for this article.

Ask the Expert

Flu expert

Dr Heidi van Deventer completed her MBChB (Bachelor of Medicine and Bachelor of Surgery) degree in 2004 at the University of Stellenbosch.
She has additional training in ACLS (Advanced Cardiac Life Support) and PALS (Paediatric Advanced Life Support) as well as biostatistics and epidemiology.

Dr Van Deventer is currently working as a researcher at the Desmond Tutu Tuberculosis Centre at the University of Stellenbosch.

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules